Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 (1 % and 2 %) Versus Placebo in Impetigo

NCT01803035 is registered in ClinicalTrials.gov with Lytix Biopharma AS as lead sponsor.

NCT NCT01803035
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01803035 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 (1 % and 2 %) Versus Placebo in Impetigo
Lead sponsor
Lytix Biopharma AS
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2013
Completion date
April 30, 2014
Enrollment
210 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

non-bullous impetigo